title: Intratubal methotrexate for prevention of persistent ectopic pregnancy after salpingotomy.
abstract: OBJECTIVE
  To investigate whether frequency of persistent ectopic pregnancy after linear salpingotomy can be reduced by prophylactic administration of a single intraoperative injection of local methotrexate.
  
  
  METHODS
  Prospective, randomized, controlled trial (Canadian Task Force classification I).
  
  
  METHODS
  University-affiliated hospital.
  
  
  METHODS
  Sixty-five women with unruptured ectopic pregnancy.
  
  
  METHODS
  Laparoscopic salpingotomy with or without a single intratubal dose of methotrexate 1 mg/kg.
  
  
  RESULTS
  In the prophylaxis group, 22 patients received a single dose of intratubal methotrexate 1 mg/kg after linear salpingotomy; 43 controls had only linear salpingotomy. Six women (14%) in the control group developed persistent ectopic pregnancy, compared with none in the prophylaxis group (p <0.05).
  
  
  CONCLUSIONS
  In our opinion, intratubal methotrexate injection during laparoscopic salpingotomy is a practical option for women with unruptured ectopic pregnancy.
authors.affiliation: Departments of Obstetrics and Gynecology, University of Süleyman Demirel, Isparta 32040, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Kaya
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Babar
authors.forename: Sadik
authors.initials: S
authors.lastname: Ozmen
authors.forename: Okan
authors.initials: O
authors.lastname: Ozkaya
authors.forename: Mehmet
authors.initials: M
authors.lastname: Karci
authors.forename: Ali Riza
authors.initials: AR
authors.lastname: Aydin
authors.forename: Demir
authors.initials: D
authors.lastname: Ozbasar
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000328:Adult; D003131:Combined Modality Therapy; D005186:Fallopian Tube Patency Tests; D005187:Fallopian Tubes / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008727:Methotrexate / Q000008:administration & dosage*; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D011274:Pregnancy, Tubal / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D011322:Primary Prevention / Q000379:methods; D011446:Prospective Studies; D012016:Reference Values; D012489:Salpingostomy / Q000009:adverse effects / Q000379:methods*; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate